Akira Shimada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akira Shimada has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
- Yoichi Oikawa
Department of Endocrinology and Diabetes, Saitama Medical University, Saitama, Japan
18 shared publications Kazuma Takahashi
Department of Nursing Basic Science, School of Nursing Iwate Prefectural University Takizawa Japan
11 shared publicationsHaruhiko Osawa
Department of Diabetes and Molecular Genetics, Ehime University Graduate School of Medicine, Toon, Japan
9 shared publicationsHiroshi Kajio
Department of Diabetes, Endocrinology, and Metabolism, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan
9 shared publicationsNorio Abiru
Department of Endocrinology and Metabolism, Nagasaki University Graduate School of Biomedical Science 7 , Nagasaki, Japan
8 shared publicationsTakuya Awata
Diabetes Research Center National Center for Global Health and Medicine Tokyo Japan
8 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 238, 113350
The first epidemiological study of presymptomatic type 1 diabetes among first-degree relatives in Japan: PREP-T1D study
- 1 June 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 238, 113350
Open AccessThe first epidemiological study of presymptomatic type 1 diabetes among first-degree relatives in Japan: PREP-T1D study
- Open Access
- 8 April 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (6) , 1052-1062
Life‐threatening acute complications persist among individuals with type 1 diabetes in Japan: A nationwide registry‐based cross‐sectional study
Introduction: Despite advances in insulin therapy, acute diabetic complications continue to pose a significant and potentially life‐threatening risk in type 1 diabetes. Since there have been no nationwide studies regarding acute diabetic complications in individuals with type 1 diabetes in Japan, we investigated the incidence of those complications and examined the association between the incidence and clinical factors in the patients. Materials and methods: Registry‐based cross‐sectional analyses were conducted using data from patients with type 1 diabetes from 125 medical institutions across Japan. Results: A total of 4,405 cases were registered in the database, of which 2,679 cases with confirmed diagnosis of type 1 diabetes subtypes were included in the analyses. Following insulin therapy, 18.8 and 7.8% of the patients experienced diabetic ketosis and diabetic ketoacidosis, respectively. Furthermore, 12.7 and 28.9% of the participants experienced severe hypoglycemia and hypoglycemic unawareness, respectively. C‐peptide levels were significantly lower in patients with these complications than in those without the complications. Notably, the incidence of these complications in patients with slowly progressive type 1 diabetes “definite” was comparable with those in patients with acute‐onset or fulminant type 1 diabetes. Conclusions: A substantial proportion of patients with type 1 diabetes in Japan experience potentially life‐threatening acute diabetic complications despite receiving insulin replacement therapy. Advanced medical care for type 1 diabetes should be further developed in this country.
- 8 April 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (6) , 1052-1062
Open AccessLife‐threatening acute complications persist among individuals with type 1 diabetes in Japan: A nationwide registry‐based cross‐sectional study
Introduction: Despite advances in insulin therapy, acute diabetic complications continue to pose a significant and potentially life‐threatening risk in type 1 diabetes. Since there have been no nationwide studies regarding acute diabetic complications in individuals with type 1 diabetes in Japan, we investigated the incidence of those complications and examined the association between the incidence and clinical factors in the patients. Materials and methods: Registry‐based cross‐sectional analyses were conducted using data from patients with type 1 diabetes from 125 medical institutions across Japan. Results: A total of 4,405 cases were registered in the database, of which 2,679 cases with confirmed diagnosis of type 1 diabetes subtypes were included in the analyses. Following insulin therapy, 18.8 and 7.8% of the patients experienced diabetic ketosis and diabetic ketoacidosis, respectively. Furthermore, 12.7 and 28.9% of the participants experienced severe hypoglycemia and hypoglycemic unawareness, respectively. C‐peptide levels were significantly lower in patients with these complications than in those without the complications. Notably, the incidence of these complications in patients with slowly progressive type 1 diabetes “definite” was comparable with those in patients with acute‐onset or fulminant type 1 diabetes. Conclusions: A substantial proportion of patients with type 1 diabetes in Japan experience potentially life‐threatening acute diabetic complications despite receiving insulin replacement therapy. Advanced medical care for type 1 diabetes should be further developed in this country.
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (11) , 1173-1184
Observational study of the relationship between the use of real-time continuous glucose monitoring and glycemic control in patients with diabetes in Japan: the REALJ study
Although randomized controlled trials have demonstrated the efficacy of real-time continuous glucose monitoring (rtCGM), evidence from routine clinical practice remains limited, particularly in Asian populations. This study aimed to evaluate the effectiveness and safety of rtCGM initiation in individuals with diabetes. This multicenter, single-arm, retrospective, observational study was conducted at 34 sites across Japan (Clinical trial registration: UMIN000054275). Adults ≥18 years of age with diabetes who began using the Dexcom G6 rtCGM system, had a baseline glycated hemoglobin (HbA1c) level ≥7.5%, and continued rtCGM for at least 26 weeks were included. Factors associated with changes in HbA1c levels were examined using multivariate linear regression models. Among 192 participants, the mean HbA1c levels at 26 weeks were significantly lower (8.62 ± 1.14% vs. 7.88 ± 1.16%, p < 0.001) than those at baseline, with a difference of –0.73 ± 1.03%. In the multivariate analysis, greater HbA1c reduction was independently associated with higher baseline HbA1c (β = –0.40; p < 0.001), longer CGM active time (β = –0.008; p = 0.043), and older age (β = –0.010; p = 0.012), whereas prior isCGM use was associated with smaller reductions (β = +0.28; p = 0.045). Sex was also independently associated with changes in HbA1c levels (p = 0.028). During the 26-week follow-up period, one patient (0.5%) experienced diabetic ketoacidosis and four individuals (2.1%) experienced severe hypoglycemia. rtCGM initiation was associated with significantly lower HbA1c levels after 26 weeks of rtCGM use. These findings support the efficacy and safety of the Dexcom G6 in routine clinical practice.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (11) , 1173-1184
Open AccessObservational study of the relationship between the use of real-time continuous glucose monitoring and glycemic control in patients with diabetes in Japan: the REALJ study
Although randomized controlled trials have demonstrated the efficacy of real-time continuous glucose monitoring (rtCGM), evidence from routine clinical practice remains limited, particularly in Asian populations. This study aimed to evaluate the effectiveness and safety of rtCGM initiation in individuals with diabetes. This multicenter, single-arm, retrospective, observational study was conducted at 34 sites across Japan (Clinical trial registration: UMIN000054275). Adults ≥18 years of age with diabetes who began using the Dexcom G6 rtCGM system, had a baseline glycated hemoglobin (HbA1c) level ≥7.5%, and continued rtCGM for at least 26 weeks were included. Factors associated with changes in HbA1c levels were examined using multivariate linear regression models. Among 192 participants, the mean HbA1c levels at 26 weeks were significantly lower (8.62 ± 1.14% vs. 7.88 ± 1.16%, p < 0.001) than those at baseline, with a difference of –0.73 ± 1.03%. In the multivariate analysis, greater HbA1c reduction was independently associated with higher baseline HbA1c (β = –0.40; p < 0.001), longer CGM active time (β = –0.008; p = 0.043), and older age (β = –0.010; p = 0.012), whereas prior isCGM use was associated with smaller reductions (β = +0.28; p = 0.045). Sex was also independently associated with changes in HbA1c levels (p = 0.028). During the 26-week follow-up period, one patient (0.5%) experienced diabetic ketoacidosis and four individuals (2.1%) experienced severe hypoglycemia. rtCGM initiation was associated with significantly lower HbA1c levels after 26 weeks of rtCGM use. These findings support the efficacy and safety of the Dexcom G6 in routine clinical practice.
- Open Access
- 15 September 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (5) , e005229
Slowly progressive type 1 diabetes and female sex as associated factors for pancreatic abnormalities on diagnostic imaging indicating precancerous potential
Introduction: This study aimed to identify factors associated with pancreatic abnormal findings on imaging (PAI) suggesting precancerous potential between slowly progressive type 1 diabetes and acute-onset type 1 diabetes. Research design and Methods: The study was designed to identify factors associated with PAI using data from a nationwide cohort, the Japanese Type 1 Diabetes Database. Clinical factors, including sex, age, type of diabetes onset, diabetes duration, body mass index, and human leucocyte antigen genotypes associated with type 1 diabetes, were evaluated. Results: Among 279 patients with type 1 diabetes, 95 patients who had not undergone imaging evaluations, two patients with pancreatic lipomatosis, and 15 patients with missing data were excluded. Finally, a total of 167 patients with type 1 diabetes were analyzed. Among 13 patients who were identified as PAI positive, female sex (92.3% vs 53.2%, p=0.007), slowly progressive type 1 diabetes (69.2% vs 36.4%, p=0.034), and older age were more common compared with PAI-negative cases. The multivariable logistic regression analysis revealed that female sex (OR 13.87; 95% CI 1.6 to 120.1; p=0.017), slowly progressive type 1 diabetes (OR 5.70; 95% CI 1.46 to 22.19; p=0.012), and age (OR 1.05; 95% CI 1.002 to 1.103; p=0.043) were independently associated with PAI positivity. Conclusions: The findings indicate that slowly progressive type 1 diabetes and female sex are closely associated with PAI, along with age. These results suggest the need for increased clinical vigilance for pancreatic pathology in patients with slowly progressive type 1 diabetes.
- 15 September 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (5) , e005229
Open AccessSlowly progressive type 1 diabetes and female sex as associated factors for pancreatic abnormalities on diagnostic imaging indicating precancerous potential
Introduction: This study aimed to identify factors associated with pancreatic abnormal findings on imaging (PAI) suggesting precancerous potential between slowly progressive type 1 diabetes and acute-onset type 1 diabetes. Research design and Methods: The study was designed to identify factors associated with PAI using data from a nationwide cohort, the Japanese Type 1 Diabetes Database. Clinical factors, including sex, age, type of diabetes onset, diabetes duration, body mass index, and human leucocyte antigen genotypes associated with type 1 diabetes, were evaluated. Results: Among 279 patients with type 1 diabetes, 95 patients who had not undergone imaging evaluations, two patients with pancreatic lipomatosis, and 15 patients with missing data were excluded. Finally, a total of 167 patients with type 1 diabetes were analyzed. Among 13 patients who were identified as PAI positive, female sex (92.3% vs 53.2%, p=0.007), slowly progressive type 1 diabetes (69.2% vs 36.4%, p=0.034), and older age were more common compared with PAI-negative cases. The multivariable logistic regression analysis revealed that female sex (OR 13.87; 95% CI 1.6 to 120.1; p=0.017), slowly progressive type 1 diabetes (OR 5.70; 95% CI 1.46 to 22.19; p=0.012), and age (OR 1.05; 95% CI 1.002 to 1.103; p=0.043) were independently associated with PAI positivity. Conclusions: The findings indicate that slowly progressive type 1 diabetes and female sex are closely associated with PAI, along with age. These results suggest the need for increased clinical vigilance for pancreatic pathology in patients with slowly progressive type 1 diabetes.
- Open Access
- 18 August 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (11) , 2101-2110
Effectiveness of the presence of diabetologists for perioperative complications in patients with diabetes undergoing colorectal cancer surgery: A nationwide inpatient database in Japan
Aims/Introduction: Little is known about the effect of diabetologists on perioperative complication risk. Given that colorectal cancer surgery is known to carry a high complication risk among patients with diabetes, this study aimed to examine the association between the presence of diabetologists at the facility level and the risk of perioperative complications during colorectal cancer surgery. Materials and Methods: In this retrospective cohort study, we sourced the number of board‐certified diabetologists from the Japan Diabetes Society and combined it with Diagnosis Procedure Combination (DPC) data, encompassing receipt data from acute care facilities across Japan. We used a modified Poisson model to estimate the risk of perioperative complications associated with the presence of diabetologists by adjusting for potential confounding patient and facility factors. Results: Analysis included 887 facilities, of which 299 (34%) had no diabetologists. A total of 24,714 patients with diabetes underwent colorectal cancer surgery between April 2018 and March 2019, with a median age of 73 years (interquartile range: 67–79 years) and 16,274 (66%) men. There were 3,165 (13%) perioperative complications. After adjustment, the risk of perioperative complications was 0.86 times (95% confidence interval: 0.77–0.96) lower in centers with at least one diabetologist than in those without a diabetologist. Conclusions: Our study suggests that the presence of a diabetologist may be important in reducing the risk of perioperative complications during colorectal cancer surgery in patients with diabetes. Future studies factoring in other facility factors and surgical types may be required to further validate our findings.
- 18 August 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (11) , 2101-2110
Open AccessEffectiveness of the presence of diabetologists for perioperative complications in patients with diabetes undergoing colorectal cancer surgery: A nationwide inpatient database in Japan
Aims/Introduction: Little is known about the effect of diabetologists on perioperative complication risk. Given that colorectal cancer surgery is known to carry a high complication risk among patients with diabetes, this study aimed to examine the association between the presence of diabetologists at the facility level and the risk of perioperative complications during colorectal cancer surgery. Materials and Methods: In this retrospective cohort study, we sourced the number of board‐certified diabetologists from the Japan Diabetes Society and combined it with Diagnosis Procedure Combination (DPC) data, encompassing receipt data from acute care facilities across Japan. We used a modified Poisson model to estimate the risk of perioperative complications associated with the presence of diabetologists by adjusting for potential confounding patient and facility factors. Results: Analysis included 887 facilities, of which 299 (34%) had no diabetologists. A total of 24,714 patients with diabetes underwent colorectal cancer surgery between April 2018 and March 2019, with a median age of 73 years (interquartile range: 67–79 years) and 16,274 (66%) men. There were 3,165 (13%) perioperative complications. After adjustment, the risk of perioperative complications was 0.86 times (95% confidence interval: 0.77–0.96) lower in centers with at least one diabetologist than in those without a diabetologist. Conclusions: Our study suggests that the presence of a diabetologist may be important in reducing the risk of perioperative complications during colorectal cancer surgery in patients with diabetes. Future studies factoring in other facility factors and surgical types may be required to further validate our findings.
- 13 June 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (8) , 1438-1445
Rapid and Slow Progressors Toward β-Cell Depletion and Their Predictors in Type 1 Diabetes: Prospective Longitudinal Study in Japanese Type 1 Diabetes (TIDE-J)
OBJECTIVE: This study aimed to investigate the progression of β-cell dysfunction and its predictors in Japanese patients with type 1 diabetes, using data from the nationwide, multicenter, prospective longitudinal Japanese Type 1 Diabetes Database Study (TIDE-J). RESEARCH DESIGN AND METHODS: TIDE-J enrolled 314 Japanese individuals with type 1 diabetes, including 165 with acute-onset, 105 with slowly progressive, and 44 with fulminant type 1 diabetes. Clinical data, including C-peptide levels, glycemic control, and autoantibody status, were collected annually for up to 14 years. HLA genotypes were analyzed at study entry. The time to insulin depletion was analyzed using survival curves and Cox proportional hazards models to determine predictive factors. RESULTS: The rate of undetectable C-peptide varied significantly among subtypes. At 5 years after onset, 43.1% (n = 55) of patients with acute-onset, 9.1% (n = 7) with slowly progressive, and 93.2% (n = 38) with fulminant type 1 diabetes reached undetectable C-peptide. Even within acute-onset type 1 diabetes, a marked interindividual variation was observed in the progression toward β-cell depletion. HLA genotypes influenced progression rates as follows: DRB1*04:05-DQB1*04:01/DRB1*04:05-DQB1*04:01 (DR4/DR4) carriers exhibited slower β-cell depletion, whereas DR4/DRB1*08:02-DQB1*03:02 (i.e., DR4/DR8) and DR4/DRB1*09:01-DQB1*03:03 (i.e., DR4/DR9) were associated with a rapid progression. For slowly progressive type 1 diabetes, low BMI, GAD antibody positivity, and absence of the DRB1*15:01-DQB1*06:02 or DRB1*15:02-DQB1*06:01 (i.e., DR2) haplotype were predictive of progression to insulin dependence. CONCLUSIONS: This study elucidates the heterogeneity in β-cell dysfunction among Japanese individuals with type 1 diabetes and identifies genetic and clinical predictors of disease progression. These findings provide insights for individualized management strategies and future therapeutic interventions.
- 13 June 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (8) , 1438-1445
Rapid and Slow Progressors Toward β-Cell Depletion and Their Predictors in Type 1 Diabetes: Prospective Longitudinal Study in Japanese Type 1 Diabetes (TIDE-J)
OBJECTIVE: This study aimed to investigate the progression of β-cell dysfunction and its predictors in Japanese patients with type 1 diabetes, using data from the nationwide, multicenter, prospective longitudinal Japanese Type 1 Diabetes Database Study (TIDE-J). RESEARCH DESIGN AND METHODS: TIDE-J enrolled 314 Japanese individuals with type 1 diabetes, including 165 with acute-onset, 105 with slowly progressive, and 44 with fulminant type 1 diabetes. Clinical data, including C-peptide levels, glycemic control, and autoantibody status, were collected annually for up to 14 years. HLA genotypes were analyzed at study entry. The time to insulin depletion was analyzed using survival curves and Cox proportional hazards models to determine predictive factors. RESULTS: The rate of undetectable C-peptide varied significantly among subtypes. At 5 years after onset, 43.1% (n = 55) of patients with acute-onset, 9.1% (n = 7) with slowly progressive, and 93.2% (n = 38) with fulminant type 1 diabetes reached undetectable C-peptide. Even within acute-onset type 1 diabetes, a marked interindividual variation was observed in the progression toward β-cell depletion. HLA genotypes influenced progression rates as follows: DRB1*04:05-DQB1*04:01/DRB1*04:05-DQB1*04:01 (DR4/DR4) carriers exhibited slower β-cell depletion, whereas DR4/DRB1*08:02-DQB1*03:02 (i.e., DR4/DR8) and DR4/DRB1*09:01-DQB1*03:03 (i.e., DR4/DR9) were associated with a rapid progression. For slowly progressive type 1 diabetes, low BMI, GAD antibody positivity, and absence of the DRB1*15:01-DQB1*06:02 or DRB1*15:02-DQB1*06:01 (i.e., DR2) haplotype were predictive of progression to insulin dependence. CONCLUSIONS: This study elucidates the heterogeneity in β-cell dysfunction among Japanese individuals with type 1 diabetes and identifies genetic and clinical predictors of disease progression. These findings provide insights for individualized management strategies and future therapeutic interventions.
- Open Access
- 9 April 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (6) , 989-991
Update on slowly progressive type 1 diabetes
Slowly progressive type 1 diabetes (SPIDDM) is a subtype of type 1 diabetes in which endogenous insulin secretion gradually declines over time, eventually leading to a state of insulin dependence. The diagnostic criteria for SPIDDM were revised in Japan in 2023, with more strict guidelines. In addition, a statement regarding therapeutic interventions for suspected SPIDDM cases has been issued.
- 9 April 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (6) , 989-991
Open AccessUpdate on slowly progressive type 1 diabetes
Slowly progressive type 1 diabetes (SPIDDM) is a subtype of type 1 diabetes in which endogenous insulin secretion gradually declines over time, eventually leading to a state of insulin dependence. The diagnostic criteria for SPIDDM were revised in Japan in 2023, with more strict guidelines. In addition, a statement regarding therapeutic interventions for suspected SPIDDM cases has been issued.
- 12 November 2024
- Published by Springer Nature in Diabetology International
- Vol. 16 (1) , 1-6
Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English Version)
Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.
- 12 November 2024
- Published by Springer Nature in Diabetology International
- Vol. 16 (1) , 1-6
Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English Version)
Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non-insulin-dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase-4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin-dependent state.
- Open Access
- 12 November 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (1) , 163-168
Practice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version)
Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non‐insulin‐dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase‐4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin‐dependent state.
- 12 November 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (1) , 163-168
Open AccessPractice guideline: Statement regarding treatment for suspected slowly progressive type 1 diabetes (SPIDDM; probable) cases (English version)
Insulin treatment should be introduced in patients with slowly progressive type 1 diabetes (SPIDDM; definite), according to the revised diagnostic criteria of SPIDDM (2023). In contrast, SPIDDM (probable) patients are in a non‐insulin‐dependent state; therefore, a more flexible treatment can be considered, although sulfonylurea agents should be avoided. Insulin treatment has been shown to maintain endogenous insulin secretion capacity in SPIDDM (probable); however, this does not mean that all SPIDDM (probable) patients should use insulin from the early phase. Dipeptidyl peptidase‐4 inhibitors and biguanides might be the treatment of choice for SPIDDM (probable), but no evidence exists for other hypoglycemic agents. In any case, careful monitoring of the endogenous insulin secretion capacity should be carried out, and if a decrease in insulin secretion capacity is suspected, a change in treatment should be considered to prevent progression to an insulin‐dependent state.
- Open Access
- 7 September 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (11) , 1578-1584
Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data
Adherence and treatment continuation rates of the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) semaglutide for both oral (O‐SEMA) and subcutaneous injection (SEMA‐SC) remain unknown in real‐world clinical practice. This retrospective observational study compared the 12 month adherence and treatment discontinuation of O‐SEMA and once‐weekly SEMA‐SC in patients with type 2 diabetes using a real‐world claims database. SEMA‐SC initiators were 1:1 propensity score‐matched to O‐SEMA initiators. Non‐adherence was defined as <0.8 of the proportion of days covered. SEMA‐SC had a significantly higher odds ratio (OR) for non‐adherence than O‐SEMA (OR: 1.39). The hazard ratio for treatment discontinuation, using O‐SEMA as the reference, was 1.45 for SEMA‐SC, although the discontinuation rate of O‐SEMA was higher during the early stage. O‐SEMA initiators showed significantly higher adherence and greater persistence in therapy than SEMA‐SC initiators at 12 months, which could lead to earlier initiation of GLP‐1RA treatment.
- 7 September 2024
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 15 (11) , 1578-1584
Open AccessAdherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data
Adherence and treatment continuation rates of the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) semaglutide for both oral (O‐SEMA) and subcutaneous injection (SEMA‐SC) remain unknown in real‐world clinical practice. This retrospective observational study compared the 12 month adherence and treatment discontinuation of O‐SEMA and once‐weekly SEMA‐SC in patients with type 2 diabetes using a real‐world claims database. SEMA‐SC initiators were 1:1 propensity score‐matched to O‐SEMA initiators. Non‐adherence was defined as <0.8 of the proportion of days covered. SEMA‐SC had a significantly higher odds ratio (OR) for non‐adherence than O‐SEMA (OR: 1.39). The hazard ratio for treatment discontinuation, using O‐SEMA as the reference, was 1.45 for SEMA‐SC, although the discontinuation rate of O‐SEMA was higher during the early stage. O‐SEMA initiators showed significantly higher adherence and greater persistence in therapy than SEMA‐SC initiators at 12 months, which could lead to earlier initiation of GLP‐1RA treatment.